Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816736 · ClinicalTrials.gov registry record · Phase 4
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 365
- Enrollment target
NCT02816736 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 365 participants.
The verdict
NCT02816736, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 365 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether, in patients with symptomatic, advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect hemodynamic and clinical status, compared to treatment with valsartan.
Interventions
- DRUG LCZ696
- DRUG valsartan
- DRUG LCZ696 placebo
- DRUG valsartan placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2020-09-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02816736
The ClinicalTrials.gov registry entry for NCT02816736 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LCZ696 is the first listed.
NCT02816736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02816736 about?
NCT02816736 is a clinical study titled "EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)". The primary objective of the study is to determine whether, in patients with symptomatic, advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect hemodynamic and clinical sta...
What is the current status of trial NCT02816736?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 365 participants. The study started on 2017-03-02. Estimated completion is 2020-09-29.
What interventions are being tested in trial NCT02816736?
The interventions under investigation include: LCZ696 (DRUG), valsartan (DRUG), LCZ696 placebo (DRUG), valsartan placebo (DRUG).
Who is sponsoring clinical trial NCT02816736?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.